Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Development of humoral and cellular immune response in infants after pneumococcal conjugate vaccinations
2011-002103-15Phase 4Completed
- Sponsor
- National Institute for Public Health and the Environment
- Start
- Aug 2013
- Modality
- Vaccines & Immunotherapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4 trial of 10-valent pneumococcal conjugate vaccine and pneumococcal 13-valent conjugate vaccine in pneumococcal disease (2 arms), sponsored by National Institute for Public Health and the Environment. Primary endpoints: Humoral immunogenicity after booster, Cellular immunogenicity after booster and 1 more. Started Aug 2013; status: completed.
02
Drugs
10-valent pneumococcal conjugate vaccinepneumococcal 13-valent conjugate vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on 2011-002103-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002103-15.